Potential Use of Biomarker γ-H2AX on Peripheral Blood Patient Who Underwent Radioiodine Ablation Treatment in Indonesia

IIN KURNIA HASAN BASRI

Abstract


Thyroid cancer is one of the most common endocrine malignancies. Although the 10-year survival rate of differentiated thyroid cancer (DTC) is about 90% after conventional treatments, a small proportion of patients still suffer from tumor recurrence or drug resistance. DNA doublestrand breaks (DSBs) are important cellular lesions that can result from ionizing radiation exposure. The biomarker for DSB formation is the phosphorylated form of the histone H2 variant H2AX (γ-H2AX). We propose the use of γ-H2AX as a DNA DSB biomarker in thyroid cancer patients receiving radioiodine treatment as a possibility to detect the potential of instability genome after receiving the treatment. Evaluating DNA DSB damage with γ-H2AX biomarker might be important in managing thyroid cancer.

Keywords


γ-H2AX, radioiodine ablation, thyroid cancer

Full Text: View | Download

DOI: 10.33371/ijoc.v15i2.764

Article Metrics

Abstract View: 369,
PDF Download: 286
             

References


Ross DS. Radioiodine therapy for hyperthyroidism. N Eng J Med. 2011;364(6):542-50.

Mazzaferri El, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.

Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(23):1054-67.

Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab. 2008;22(6):989–1007.

Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941-59.

Hurley JR, Becker DV. Treatment of thyroid carcinoma with radioiodine. In: Gottshalk A, Hoffer PB, Potchen EJ, editors. Diagnostic nuclear medicine. 2nd ed. Baltimore: Williams & Wilkins; 1988. p. 792–814.

Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. Hong Kong J Radiol. 2005;8:127–35.

American Thyroid Association Taskforce on Radioiodine Safety, Sisson JC, Freitas J, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011;21(4): 335-46.

Perros S, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81 Suppl 1:1-122.

Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341-9.

Watanabe N, Kanegane K, Kinuya S, et al. The radiotoxicity of 131l therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med. 2004;45(4):608-11.

Hunt CR, Deepty R, Nobuo H, et al. Histone modifications and DNA double-strand break repair after exposure to ionizing radiations. Radiat Res. 2013;179(4):383-92.

Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36(17): 5678-94.

Jakob B, Splinter J, Conrad S, et al. DNA double-strand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin. Nucleic Acids Res. 2011;39(15):6489-99.

Rothkamm K, Löbrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci. 2003;100(9):5057-62.

Basri IKH, Yusuf D, Rahardjo T, et al. Study of ɣ-H2AX as DNA double strand break biomarker in resident living in high natural radiation area of Mamuju, West Sulawesi. J Environ Radioact. 2017;171:212-6.

Kuefner MA, Grudzenski S, Hamann J, et al. Effect of CT scan protocols on x-ray-induced DNA double-strand breaks in blood lymphocytes of patients undergoing coronary CT angiography. Euro Radiol. 2010;20(12):2917-24.

Horn S, Barnard S, Rothkamm K. Gamma-H2AX-based dose estimation for whole and partial body radiation exposure. PloS One. 2011;6(9):e25113.

Wouters BG, Begg AC. Irradiation-induced damage and the DNA damage response. In: Joiner MC, van der Kogel A, editors. Basic clinical radiobiology. 4th ed. Boca Raton: Taylor & Francis Group; 2009. p. 11-26.

Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010;28(34):5061-6.

Jeggo PA, Löbrich M. DNA double-strand breaks: their cellular and clinical impact?. Oncogene. 2007;26(56):7717-9.

Rothkamm K, Horn S. Gamma-H2AX as protein biomarker for radiation exposure. Ann Super Sanita. 2009;45(3):265-71.

Pernot E, Hall J, Baatout S, et al. Ionizing radiation biomarkers for potential use in epidemiological studies. Mutat Res. 2012;751(2):258-86.

Goodarzi AA, Jeggo PA. The repair and signaling responses to DNA double-strand breaks. Adv Genet. 2013;82:1–45.

Goodarzi AA, Jeggo PA. Irradiation induced foci (IRIF) as a biomarker for radiosensitivity. Mutat Res. 2012;736:39–47.

Denoyer D, Lobachevsky P, Jackson P, et al. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J Nucl Med. 2015;56:505–511.

Koch U, Hohne K, Von Neubeck C, et al. Residual γ-H2AX foci predict local tumour control after radiotherapy. Radiother Oncol. 2013;108(3):434–9.

Wahidin M, Noviani R, Hermawan S, et al. Population-based cancer registration in Indonesia. Asian Pac J Cancer Prev. 2012;13(4):1709-10.

World Health Organization. Indonesian Globocan 2018 [internet]; International Agency for Research in Cancer; 2020 [cited 2021 Jan 30]. available from: gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf.

Fisher DA. Physiological variations in thyroid hormones: physiological and pathophysiological considerations. Clin Chem. 1996;42(1):135-9.

Cooper DS. Hyperthyroidism. Lancet. 2003;362(9382):459-68.

McDermott MT, Woodmansee WW, Haugen BR, et al. The management of subclinical hyperthyroidism by thyroid specialists. Thyroid. 2003;13(12):1133-9.

Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24(1):102-32.

Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S150-60.

Wyszomirska A. Iodine-131 for therapy of thyroid diseases physical and biological basis. Nucl Med Rev Cent East Eur. 2012;15(2):120-3.

Doai M, Watanabe N, Takahashi T, et al. Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes. Ann Nucl Med. 2013;27(3):233-8.

Eberlein U, Scherthan H, Bluemel C, et al. DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy. J Nucl Med. 2016;57(2):173-9.

Eberlein U, Nowak C, Bluemel C, et al. DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1739-49.

Yoshinaga S, Mabuchi K, Sigurdson AJ, et al. Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. Radiology. 2004;233(2):313-21.

United Nations. Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation: sources. Vol. 1. United Nations Publications, 2000.

Dobrzyńska MM, Pachocki KA, Gajowik A, et al. The effect occupational exposure to ionizing radiation on the DNA damage in peripheral blood leukocytes of nuclear medicine personnel. J Occup Health. 2014;56(5):379-86.

International Comission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection [internet]. ICRP publication 60; 1991 [cited 2021 Jan 29]. Available from: http://journals.sagepub.com/doi/pdf/10.1177/ANIB_21_1-3

Kurnia I, Lusiyanti Y , Rahajeng N. Expression of γ-H2AX in nuclear medicine and cath lab as medical radiation workers. The Proceedings Book 8th Annual Basic Science International Conferences 2018. 2018:357-62.

Basri IKH, Lusiyanti Y, Rahajeng N, et al. Preliminary study of expression of gamma H2AX and 53BP1 in Medical Radiation Workers. Radiat Environ Med. 2019;8(2):70-6.

Dadong I, Bunawas S. Mapping radiation and radioactivity in Sulawesi island. The Third Asian and Oceanic Congress on Radiation Protection (AOCRP-3). 2010.

Syaeful H, Sukadana IG, Sumaryanto A. Radiometric mapping for naturally occurring radioactive materials (NORM) assessment in Mamuju, West Sulawesi. Atom Indones. 2014;40(1):33-9.

United Nations Scientific Committee on the Effects of Atomic Radiation. Hereditary Effects of Radiation [internet]. New York: United Nations; 2001 [cited 2020 Dec 15]. Available from: https://www.unscear.org/docs/publications/2001/UNSCEAR_2001_Report.pdf

Sankaranayanan K, Chakraborty C. Ionizing radiation and genetic risks: XI. The doubling dose estimates from the mid-1950s to the present and the conceptual change to the use of human data on spontaneous mutation rates and mouse data on induced mutation rates for doubling dose calculations. Mutat Res. 2000;453(2):107-27.

Garm C, Moreno-Villanueva M, Burkle A, et al. Age and gender effects on DNA strand break repair in peripheral blood mononuclear cells. Aging Cell. 2013;12(1):58-66.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.